78885
document
Adjuvant therapy of breast cancer : the Southwest Oncology Group experience . The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP ( cyclophosphamide , methotrexate , 5-fluorouracil , vincristine , and prednisone ) to two years of intermittent L-phenylalanine mustard ( L-PAM ) in women with operable breast cancer with histologically positive axillary lymph nodes . In fully and partially evaluable patients with a 68-month median follow-up , treatment failures have occurred in 27 % of 172 receiving CMFVP and 47 % of 186 women given L-PAM ( p = 0.002 ) . The advantage for women receiving CMFVP was seen for all subsets regardless of menopausal status except among women who were premenopausal and had 1-3 positive nodes . Based on this study , a second study was implemented using both the estrogen-receptor ( ER ) content of the primary tumor and axillary nodal status to select therapy .
78886
Intervention_Physical
Adjuvant therapy
78887
Intervention_Pharmacological
adjuvant combination chemotherapy with continuous CMFVP ( cyclophosphamide , methotrexate , 5-fluorouracil , vincristine , and prednisone ) to two years of intermittent L-phenylalanine mustard ( L-PAM )
78888
Intervention_Pharmacological
CMFVP
78889
Intervention_Pharmacological
L-PAM
78890
Intervention_Pharmacological
CMFVP
78891
Outcome_Physical
treatment failures
78892
Participant_Sex
women
78893
Participant_Condition
with operable breast cancer with histologically positive axillary lymph nodes .
78894
Participant_Sample-size
172
78895
Participant_Sample-size
186
78896
Participant_Condition
premenopausal